Evidence map›Paper›PMID 39456538›Full record

ReviewCancers2024

Immunotherapeutic Potential of Mutated NPM1 for the Treatment of Acute Myeloid Leukemia.

Jochen Greiner, Eithar Mohamed, Daniel M Fletcher, Patrick J Schuler, Hubert Schrezenmeier, Marlies Götz, Barbara-Ann Guinn

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Cancers · 2025
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jochen GreinerDepartment of Internal Medicine III, University Hospital Ulm, 89081 Ulm, Germany.ORCID 0000-0003-1256-173X
Eithar MohamedCentre for Biomedicine, Hull York Medical School, University of Hull, Hull HU6 7RX, UK.
Daniel M FletcherCentre for Biomedicine, Hull York Medical School, University of Hull, Hull HU6 7RX, UK.ORCID 0000-0002-6847-841X
Patrick J SchulerDepartment of Otorhinolaryngology, University Hospital Ulm, 89075 Ulm, Germany.ORCID 0000-0002-1065-8709
Hubert SchrezenmeierInstitute of Transfusion Medicine, University of Ulm, 89073 Ulm, Germany.
Marlies GötzDepartment of Internal Medicine III, University Hospital Ulm, 89081 Ulm, Germany.
Barbara-Ann GuinnCentre for Biomedicine, Hull York Medical School, University of Hull, Hull HU6 7RX, UK.ORCID 0000-0003-0639-4541

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute myeloid leukemia (AML) is a malignant disease of the blood and bone marrow that is characterized by uncontrolled clonal proliferation of abnormal myeloid progenitor cells. Nucleophosmin 1 (NPM1) gene mutations are the most common genetic abnormality in AML, detectable in blast cells from about one-third of adults with AML. AML NPM1

Indexed as

acute myeloid leukemiaimmunogenic subtypeimmunotherapyNPM1 mutationprogrammed death ligand 1

Identifiers

PMID39456538
PMCPMC11505958

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.